Daniel Silverman

Daniel Silverman, MD, PhD

Clinical Professor, Department of Molecular and Medical Pharmacology
Head, Neuronuclear Imaging Section, Ahmanson Biological Imaging Division, UCLA Medical Center




Nuclear Medicine



Medicine/Nuclear Medicine, UCLA School of Medicine, 1994 - 1996


Internal Medicine, UCLA School of Medicine, 1992 - 1993


MD, Ohio State University College of Medicine, 1992
PhD, Harvard University, 1987


Internal Medicine, UCLA School of Medicine, 1993 - 1994

Board Certifications

Nuclear Medicine, American Board of Nuclear Medicine, 1996
Internal Medicine, American Board of Internal Medicine, 1995

Contact Information

Scientific Interests

The two major goals of Dr. Daniel Silverman's research program are to explore in the living human brain the interactions and neurologic bases of memory, mood and pain perception - with respect to both normal and disordered function (as occurs in dementia, depression and chronic pain syndromes) and to develop noninvasive methodologies with which to optimize management of breast and colorectal cancers.

These apparently disparate objectives are united through use of low-level radioactive biochemicals to characterize and map in the human body the distribution of processes having pressing relevance to patients seen in nuclear and internal medicine. Both lines of research involve extensive application of positron emission tomography (PET). With a focus ranging from molecular processes to human behaviors, research activities correspondingly span the "bench to bedside" spectrum from biochemical work in vitro to monitoring and impacting upon progress of patients in the Ahmanson Biological Imaging Clinic.

Highlighted Publications

Rasgon NL, Geist CL, Kenna HA, Wroolie TE, Williams KE, Silverman DH. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS One. 2014 Mar 12;9(3):e89095. doi: 10.1371/journal.pone.0089095. eCollection 2014.

Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C, Breen EC, Irwin MR, Cole SW. Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013 Mar;30 Suppl:S99-108. doi: 10.1016/j.bbi.2012.07.015. Epub 2012 Aug 3.

Pomykala KL, Ganz PA, Bower JE, Kwan L, Castellon SA, Mallam S, Cheng I, Ahn R, Breen EC, Irwin MR, Silverman DH. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 2013 Dec;7(4):511-23. doi: 10.1007/s11682-013-9243-2.

Saykin AJ, de Ruiter MB, McDonald BC, Deprez S, Silverman DH. Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav. 2013 Dec;7(4):363-73. doi: 10.1007/s11682-013-9283-7.

Pomykala KL, Silverman DH, Geist CL, Voege P, Siddarth P, Nazarian N, St Cyr NM, Khalsa DS, Lavretsky H. A pilot study of the effects of meditation on regional brain metabolism in distressed dementia caregivers. Aging health. 2012 Oct 1;8(5):509-516.